Steroid hormone synthetic pathways in prostate cancer
While androgen deprivation therapy (ADT) remains the primary treatment for metastatic prostate cancer (PCa) since the seminal recognition of the disease as androgen-dependent by Huggins and Hodges in 1941, therapy is uniformly marked by progression to castration-resistant prostate cancer (CRPC) over...
Main Author: | Mostaghel, Elahe A. |
---|---|
Format: | Online |
Language: | English |
Published: |
AME Publishing Company
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219921/ |
Similar Items
-
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel, Elahe A
Published: (2014) -
Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
by: Mostaghel, Elahe A
Published: (2014) -
Glucocorticoids and prostate cancer treatment: friend or foe?
by: Montgomery, Bruce, et al.
Published: (2014) -
Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.
by: Zarghami, N., et al.
Published: (1997) -
Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting
by: Kumar, Raj
Published: (2016)